BRAF and colorectal carcinoma: Cremolini et al. (2018) also studied the response of patients to re-challenge with cetuximab following the initial development of resistance to this treatment. Metastatic CRC patients whose tumors were KRAS/NRAS/BRAF WT and were initially responsive to cetuximab subsequently developed resistance.